Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review0580 has been discontinued.
View all Adrenergic α<sub>1</sub> Receptors products.Potent ligand at α1 sites (Ki = 0.3 nM). Also binds at 5-HT1A sites (Ki = 1.5 nM).
M. Wt | 447.54 |
Storage | Store at RT |
CAS Number | 133399-70-9 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Russo et al (1991) Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective α1 adrenoceptor ligands. J.Med.Chem. 34 1850 PMID: 1648138
Keywords: 3-[2-[4-(2-Methoxyphenyl)piperazin-1-yl]ethyl]-1,5-dimethylpyrimido[5,4-b]indole-2,4-dione, 3-[2-[4-(2-Methoxyphenyl)piperazin-1-yl]ethyl]-1,5-dimethylpyrimido[5,4-b]indole-2,4-dione supplier, Adrenergic, Alpha-1, Receptors, 5-HT1A, 0580, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for 3-[2-[4-(2-Methoxyphenyl)piperazin-1-yl]ethyl]-1,5-dimethyl pyrimido[5,4-b]indole-2,4-dione.
There are currently no reviews for this product. Be the first to review 3-[2-[4-(2-Methoxyphenyl)piperazin-1-yl]ethyl]-1,5-dimethyl pyrimido[5,4-b]indole-2,4-dione and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.